A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

<h4>Background</h4> <p>GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood–brain barrier (BBB) penetration. In this expansion cohort within a...

Täydet tiedot

Bibliografiset tiedot
Päätekijät:	Brown, N, Williams, M, Arkenau, H, Fleming, R, Tolson, J, Yan, L, Zhang, J, Swartz, L, Singh, R, Auger, K, Lenox, L, Cox, D, Lewis, Y, Plisson, C, Searle, G, Saleem, A, Blagden, S, Mulholland, P
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Oxford University Press 2018
Aiheet:	focal adhesions kinetics neoplasms pharmacokinetics cerebral edema fatigue positron-emission tomography brain toxic effect phosphotransferases glioblastoma safety kinase inhibitors

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098

Samankaltaisia teoksia